BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 99 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,356 | +169.0% | 191,527 | +167.8% | 0.12% | +132.0% |
| Q2 2023 | $504 | -60.7% | 71,532 | -53.5% | 0.05% | -60.6% |
| Q1 2023 | $1,282 | -99.5% | 153,718 | +703.9% | 0.13% | +296.9% |
| Q3 2022 | $241,000 | -59.2% | 19,121 | -53.5% | 0.03% | -46.7% |
| Q3 2021 | $591,000 | -27.6% | 41,116 | -48.7% | 0.06% | -55.6% |
| Q1 2021 | $816,000 | +946.2% | 80,197 | +663.8% | 0.14% | +938.5% |
| Q4 2020 | $78,000 | -58.7% | 10,500 | -73.5% | 0.01% | -87.6% |
| Q2 2020 | $189,000 | -31.8% | 39,599 | -71.4% | 0.10% | +52.2% |
| Q1 2020 | $277,000 | -15.8% | 138,664 | +243.4% | 0.07% | +109.1% |
| Q1 2019 | $329,000 | +376.8% | 40,383 | +208.6% | 0.03% | +560.0% |
| Q3 2017 | $69,000 | -84.0% | 13,086 | -63.0% | 0.01% | -83.3% |
| Q4 2014 | $430,000 | -19.6% | 35,350 | -35.3% | 0.03% | +7.1% |
| Q3 2014 | $535,000 | – | 54,674 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |